biote (NASDAQ:BTMD) & Upexi (NASDAQ:UPXI) Head to Head Comparison

biote (NASDAQ:BTMD) and Upexi (NASDAQ:UPXI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.

Insider and Institutional Ownership

21.7% of biote shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 13.9% of biote shares are owned by company insiders. Comparatively, 38.3% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares biote and Upexi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	4.30%	-36.67%	12.50%
Upexi	-28.34%	-54.97%	-23.24%

Earnings & Valuation

This table compares biote and Upexi’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$187.23 million	1.91	$3.32 million	$0.11	52.27
Upexi	$83.98 million	0.05	-$16.93 million	N/A	N/A

biote has higher revenue and earnings than Upexi.

Volatility & Risk

biote has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Upexi has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for biote and Upexi, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	0	0	4	0	3.00
Upexi	0	1	0	0	2.00

biote currently has a consensus price target of $8.39, suggesting a potential upside of 45.87%. Upexi has a consensus price target of $1.25, suggesting a potential upside of 554.11%. Given Upexi’s higher probable upside, analysts plainly believe Upexi is more favorable than biote.

Summary

biote beats Upexi on 10 of the 12 factors compared between the two stocks.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

About Upexi

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.